

Sheet 1 of 1

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50125/019001
	Serial No.	09/720,066
	Applicant	Hallek et al.
	Filing Date	October 19, 2001
	Group	1633
	IDS Filed	September 27, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION						
Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)	
mm	"Designer" Gene Therapy May Target Specific Body Area," <i>Gene Therapy, Business News</i> , January 20, 2003. Vol. 2, pg. 1-8.
	Marshall, "Second Child In French Trial is Found to Have Leukemia," <i>Science</i> 299:320 (2003).
	Shi et al., "RGD Inclusion in VP3 Provides Adeno-Associated Virus Type 2 (AAV2)-Based Vectors with a Heparan Sulfate-Independent Cell Entry Mechanism," <i>Molecular Therapy</i> 7:515-525 (2003).
	Steinbach et al., "Assembly of Adeno-Associated Virus Type 2 Capsids <i>in vitro</i> ," <i>Journal of General Virology</i> 78:1453-1462 (1997).
mm	White et al., "Targeted Gene Delivery to Vascular Tissue In Vivo by Tropism-Modified Adeno-Associated Virus Vectors," <i>Circulation</i> 109:513-519 (2004).

EXAMINER <u>W. Mannich</u>	DATE CONSIDERED <u>12/8/06</u>
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.	